Long-term effects of abatacept on atherosclerosis and arthritis in older vs. younger patients with rheumatoid arthritis: 3-year results of a prospective, multicenter, observational study
We aimed to reveal the effect of abatacept (ABT) on atherosclerosis in rheumatoid arthritis (RA) patients, 3-year efficacy for arthritis, and safety in a population of older vs. younger patients. (Source: Arthritis Research and Therapy)
Source: Arthritis Research and Therapy - April 17, 2024 Category: Rheumatology Authors: Zento Yamada, Sei Muraoka, Mai Kawazoe, Wataru Hirose, Hajime Kono, Shinsuke Yasuda, Takahiko Sugihara and Toshihiro Nanki Tags: Research Source Type: research
Long-term effects of abatacept on atherosclerosis and arthritis in older vs. younger patients with rheumatoid arthritis: 3-year results of a prospective, multicenter, observational study
CONCLUSIONS: ABT may decelerate atherosclerosis progression and may be useful for patients with high risk of cardiovascular disease, such as older patients.TRIAL REGISTRATION NUMBER: UMIN000014913.PMID:38627782 | DOI:10.1186/s13075-024-03323-8 (Source: Atherosclerosis)
Source: Atherosclerosis - April 16, 2024 Category: Cardiology Authors: Zento Yamada Sei Muraoka Mai Kawazoe Wataru Hirose Hajime Kono Shinsuke Yasuda Takahiko Sugihara Toshihiro Nanki Source Type: research
Maternal immune suppression during pregnancy does not prevent abnormal behavior in offspring
ConclusionThe results from this study suggest that offspring of hypertensive disorders of pregnancy have behavioral changes, specifically cognitive differences. This study has shown that there is a sex dependent difference in offspring neurobehavioral development, influenced in part by the type of hypertensive disorder of pregnancy, and alterations in the maternal immune system. (Source: Biology of Sex Differences)
Source: Biology of Sex Differences - March 26, 2024 Category: Biology Source Type: research
Novel Use of Abatacept and Ruxolitinib as Salvage Therapy in Steroid-Refractory Immune Checkpoint Blockade-Induced Myocarditis with Myasthenia and Myositis Overlap Syndrome
An 81-year-old female with stage IIIB melanoma presented to an outside hospital complaining of fatigue, muscle aches, shortness of breath, eyelid drooping, and difficulty swallowing. Two weeks prior, she had received her first and only dose of PD-1 blockade, nivolumab. A 12-lead electrocardiogram at the time of admission revealed sinus tachycardia at 106 beats per minute. Lab investigations were remarkable for elevated high-sensitivity troponin-T levels of 762 ng/mL (reference range (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 16, 2024 Category: Cancer & Oncology Authors: Stefano H Byer, Colten Stewart, Shareef Mansour, Udhayvir S Grewal Tags: Letter to the Editor Source Type: research
Potential efficacy of T and B lymphocyte-targeted therapies on articular involvement of patients with rheumatoid arthritis and systemic sclerosis overlap syndrome. Results from a 2-centre series of 22 cases
CONCLUSIONS: In patients with RA/SSc overlap syndrome refractory to conventional synthetic-DMARDs, T and B lymphocyte-targeted therapies seem to be a promising therapeutic option to control joint activity.PMID:38489323 (Source: Clinical and Experimental Rheumatology)
Source: Clinical and Experimental Rheumatology - March 15, 2024 Category: Rheumatology Authors: Nans Lebel Isabelle Marie Julien Grosjean Pauline Brevet Mathilde Leclercq Ana ël Dumont Herv é Levesque Ygal Benhamou Christian Marcelli Thierry Lequerre Olivier Vittecoq Source Type: research
Potential efficacy of T and B lymphocyte-targeted therapies on articular involvement of patients with rheumatoid arthritis and systemic sclerosis overlap syndrome. Results from a 2-centre series of 22 cases
CONCLUSIONS: In patients with RA/SSc overlap syndrome refractory to conventional synthetic-DMARDs, T and B lymphocyte-targeted therapies seem to be a promising therapeutic option to control joint activity.PMID:38489323 | DOI:10.55563/clinexprheumatol/0znf7e (Source: Clinical and Experimental Rheumatology)
Source: Clinical and Experimental Rheumatology - March 15, 2024 Category: Rheumatology Authors: Nans Lebel Isabelle Marie Julien Grosjean Pauline Brevet Mathilde Leclercq Ana ël Dumont Herv é Levesque Ygal Benhamou Christian Marcelli Thierry Lequerre Olivier Vittecoq Source Type: research
Overview of Rheumatoid Arthritis-Associated Interstitial Lung Disease and Its Treatment
Semin Respir Crit Care Med. 2024 Mar 14. doi: 10.1055/s-0044-1782218. Online ahead of print.ABSTRACTInterstitial lung disease (ILD) is a common pulmonary complication of rheumatoid arthritis (RA), causing significant morbidity and mortality. Optimal treatment for RA-ILD is not yet well defined. Reliable prognostic indicators are largely byproducts of prior ILD progression, including low or decreasing forced vital capacity and extensive or worsening fibrosis on imaging. In the absence of validated tools to predict treatment response, decisions about whether to initiate or augment treatment are instead based on clinical judg...
Source: Respiratory Care - March 14, 2024 Category: Respiratory Medicine Authors: Janelle Vu Pugashetti Joyce S Lee Source Type: research
Overview of Rheumatoid Arthritis-Associated Interstitial Lung Disease and Its Treatment
Semin Respir Crit Care Med DOI: 10.1055/s-0044-1782218Interstitial lung disease (ILD) is a common pulmonary complication of rheumatoid arthritis (RA), causing significant morbidity and mortality. Optimal treatment for RA-ILD is not yet well defined. Reliable prognostic indicators are largely byproducts of prior ILD progression, including low or decreasing forced vital capacity and extensive or worsening fibrosis on imaging. In the absence of validated tools to predict treatment response, decisions about whether to initiate or augment treatment are instead based on clinical judgment. In general, treatment should be initiate...
Source: Seminars in Respiratory and Critical Care Medicine - March 14, 2024 Category: Respiratory Medicine Authors: Pugashetti, Janelle Vu Lee, Joyce S. Tags: Review Article Source Type: research
Long Term Follow-Up Of Abatacept, Post-Transplantation Cyclophosphamide and Sirolimus (AbaCyS) based Haploidentical Transplantation in Younger Patients with Nonmalignant Diseases
Haploidentical (Haplo) HCT for nonmalignant diseases (NMD) faces inherent challenges of both alloreactivity and graft failure. Building upon promising results from pilot studies, where abatacept was combined with post-transplantation cyclophosphamide (PTCy) and sirolimus (AbaCyS) in younger NMD patients undergoing haplo-HCT, we present the long-term outcomes of this protocol. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - March 13, 2024 Category: Hematology Authors: Sarita Rani Jaiswal, Mahak Agarwal, Gitali Bhagawati, Bhudev Chandra Das, Prakash Baligar, Manoj Garg, Subhrajit Biswas, Suparno Chakrabarti Source Type: research
